A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide

Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
Tara GurungN Waugh

Abstract

Dulaglutide is a new, long-acting glucagon-like peptide analogue in the treatment of type 2 diabetes. It is available in two doses, 0.75 and 1.5 mg, given by injection once weekly. This systematic review reports the effectiveness and safety of dulaglutide in type 2 diabetes in dual and triple therapy. MEDLINE, MEDLINE In-Process and Other Non-Indexed Citations, EMBASE, and conference abstracts were searched from 2005 to August 2014, and updated in January 2015. Company websites and references of included studies were checked for potentially relevant studies. European Medicines Agency and US Food and Drug Administration websites were searched. Four trials were included. All were manufacturer-funded randomized controlled trials from the Assessment of Weekly Administration of Dulaglutide in Diabetes (AWARD) program. AWARD-1 compared dulaglutide 1.5 mg against exenatide 10 µg twice daily and placebo, AWARD-2 compared dulaglutide 0.75 and 1.5 mg against insulin glargine, AWARD-5 compared dulaglutide 0.75 and 1.5 mg against sitagliptin 100 mg and placebo, and AWARD-6 compared dulaglutide 1.5 mg against liraglutide 1.8 mg. The duration of follow-up in the trials ranged from 26 to 104 weeks. The primary outcome of all the included tria...Continue Reading

Citations

Oct 27, 2015·Diabetes, Obesity & Metabolism·Mark M SmitsDaniël H van Raalte
Sep 30, 2016·Expert Opinion on Biological Therapy·Marc S Rendell
Jul 6, 2017·Expert Opinion on Drug Safety·Marc S Rendell
Aug 1, 2018·Expert Review of Endocrinology & Metabolism·Marc S Rendell

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01584232

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.